Jefferies analyst Andrew Tsai has maintained their bullish stance on SVRA stock, giving a Buy rating today.
Andrew Tsai has given his Buy rating due to a combination of factors that position Savara favorably in the market. The completion of the rolling Biologics License Application (BLA) for Molbreevi, a treatment for a rare lung disease known as aPAP, is a significant milestone. With the expectation of FDA approval by late 2025, based on a priority review, the drug is poised to become the first approved therapy for this condition in the U.S., which could drive substantial market demand.
Additionally, Savara’s management is actively preparing for the market launch by expanding their field force and increasing patient diagnoses, which is expected to support rapid sales uptake. The company has also secured reliable manufacturing partnerships, ensuring supply chain stability. These strategic moves, combined with strong Phase III data and the potential for a significant valuation increase upon FDA approval, underpin Tsai’s confidence in the stock’s growth potential.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.
SVRA’s price has also changed moderately for the past six months – from $4.240 to $2.700, which is a -36.32% drop .